These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33223029)

  • 21. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms.
    Williams PC; Henner WD; Roman-Goldstein S; Dahlborg SA; Brummett RE; Tableman M; Dana BW; Neuwelt EA
    Neurosurgery; 1995 Jul; 37(1):17-27; discussion 27-8. PubMed ID: 8587686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanoparticles: Novel vehicles in treatment of Glioblastoma.
    Pourgholi F; Hajivalili M; Farhad JN; Kafil HS; Yousefi M
    Biomed Pharmacother; 2016 Feb; 77():98-107. PubMed ID: 26796272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel drug delivery strategies in neuro-oncology.
    Bidros DS; Vogelbaum MA
    Neurotherapeutics; 2009 Jul; 6(3):539-46. PubMed ID: 19560743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose chemotherapy with autologous bone marrow transplantation in the treatment of high grade astrocytomas in adults: therapeutic rationale and clinical experience.
    Fine HA; Antman KH
    Bone Marrow Transplant; 1992 Oct; 10(4):315-21. PubMed ID: 1330152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delivering siRNA and Chemotherapeutic Molecules Across BBB and BTB for Intracranial Glioblastoma Therapy.
    Yang ZZ; Gao W; Liu YJ; Pang N; Qi XR
    Mol Pharm; 2017 Apr; 14(4):1012-1022. PubMed ID: 28252970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glioblastoma multiforme: a glance at advanced therapies based on nanotechnology.
    Rezaei V; Rabiee A; Khademi F
    J Chemother; 2020 May; 32(3):107-117. PubMed ID: 31984871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leveraging the neurosurgical operating room for therapeutic development in NeuroOncology.
    Lowe SR; Kunigelis K; Vogelbaum MA
    Adv Drug Deliv Rev; 2022 Jul; 186():114337. PubMed ID: 35561836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-miR delivery strategies to bypass the blood-brain barrier in glioblastoma therapy.
    Kim DG; Kim KH; Seo YJ; Yang H; Marcusson EG; Son E; Lee K; Sa JK; Lee HW; Nam DH
    Oncotarget; 2016 May; 7(20):29400-11. PubMed ID: 27102443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glioblastoma chemotherapeutic agents used in the clinical setting and in clinical trials: Nanomedicine approaches to improve their efficacy.
    Aparicio-Blanco J; Sanz-Arriazu L; Lorenzoni R; Blanco-Prieto MJ
    Int J Pharm; 2020 May; 581():119283. PubMed ID: 32240807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic Delivery to Central Nervous System.
    Kunigelis KE; Vogelbaum MA
    Neurosurg Clin N Am; 2021 Apr; 32(2):291-303. PubMed ID: 33781509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion.
    Stummer W; van den Bent MJ; Westphal M
    Acta Neurochir (Wien); 2011 Jun; 153(6):1211-8. PubMed ID: 21479583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Getting to the brain.
    Baratta MG
    Nat Nanotechnol; 2018 Jul; 13(7):536. PubMed ID: 29921944
    [No Abstract]   [Full Text] [Related]  

  • 33. Advances in chemotherapy for brain tumors.
    Conrad CA; Milosavljevic VP; Yung WK
    Neurol Clin; 1995 Nov; 13(4):795-812. PubMed ID: 8583997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
    Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
    J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma.
    Boiardi A; Bartolomei M; Silvani A; Eoli M; Salmaggi A; Lamperti E; Milanesi I; Botturi A; Rocca P; Bodei L; Broggi G; Paganelli G
    J Neurooncol; 2005 Apr; 72(2):125-31. PubMed ID: 15925992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Computational modeling in glioblastoma: from the prediction of blood-brain barrier permeability to the simulation of tumor behavior.
    Miranda A; Cova T; Sousa J; Vitorino C; Pais A
    Future Med Chem; 2018 Jan; 10(1):121-131. PubMed ID: 29235374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
    Berenguer-Daizé C; Astorgues-Xerri L; Odore E; Cayol M; Cvitkovic E; Noel K; Bekradda M; MacKenzie S; Rezai K; Lokiec F; Riveiro ME; Ouafik L
    Int J Cancer; 2016 Nov; 139(9):2047-55. PubMed ID: 27388964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Harnessing nanomedicine for therapeutic intervention in glioblastoma.
    Gutkin A; Cohen ZR; Peer D
    Expert Opin Drug Deliv; 2016 Nov; 13(11):1573-1582. PubMed ID: 27292970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inducing a Transient Increase in Blood-Brain Barrier Permeability for Improved Liposomal Drug Therapy of Glioblastoma Multiforme.
    Lundy DJ; Lee KJ; Peng IC; Hsu CH; Lin JH; Chen KH; Tien YW; Hsieh PCH
    ACS Nano; 2019 Jan; 13(1):97-113. PubMed ID: 30532951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amphetamine decorated cationic lipid nanoparticles cross the blood-brain barrier: therapeutic promise for combating glioblastoma.
    Saha S; Yakati V; Shankar G; Jaggarapu MMCS; Moku G; Madhusudana K; Banerjee R; Ramkrishna S; Srinivas R; Chaudhuri A
    J Mater Chem B; 2020 May; 8(19):4318-4330. PubMed ID: 32330214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.